UBS lowers Amgen stock price target to $430 on drug trial concerns
UBS lowers Amgen stock price target to $430 on drug trial concerns Investing.com UK
Covered in this story
Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 26 May 2026.
Summary aggregated from Investing.com UK's public RSS feed. The full reporting belongs to Investing.com UK — please read it on their site.